-
Chakrapani Subramanyam,
Allen J Duplantier, Mark A Dombroski,
Shang-Poa Chang,
Christopher A Gabel,
Carrie Whitney-Pickett,
David G Perregaux,
Jeff M Labasi,
Kwansik Yoon,
Richard M Shepard,
Michael Fisher
[show abstract]
[hide abstract]
ABSTRACT: The discovery, of a series of 2-Cl-5-heteroaryl-benzamide antagonists of the P2X(7) receptor via parallel medicinal chemistry is described. Initial analogs suffered from poor metabolic stability and low Vd(ss). Multi parametric optimization led to identification of pyrazole 39 as a viable lead with excellent potency and oral bioavailability. Further attempts to improve the low Vd(ss) of 39 via introduction of amines led to analogs 40 and 41 which maintained the favorable pharmacology profile of 39 and improved Vd(ss) after iv dosing. But these analogs suffered from poor oral absorption, probably driven by poor permeability.
Bioorganic & medicinal chemistry letters 09/2011; 21(18):5475-9. · 2.65 Impact Factor
-
Allen J Duplantier, Mark A Dombroski,
Chakrapani Subramanyam,
Aimee M Beaulieu,
Shang-Poa Chang,
Christopher A Gabel,
Crystal Jordan,
Amit S Kalgutkar,
Kenneth G Kraus,
Jeff M Labasi,
Christopher Mussari,
David G Perregaux,
Rick Shepard,
Timothy J Taylor,
Kristen A Trevena,
Carrie Whitney-Pickett,
Kwansik Yoon
[show abstract]
[hide abstract]
ABSTRACT: High throughput screening (HTS) of our compound file provided an attractive lead compound with modest P2X(7) receptor antagonist potency and high selectivity against a panel of receptors and channels, but also with high human plasma protein binding and a predicted short half-life in humans. Multi-parameter optimization was used to address the potency, physicochemical and pharmacokinetic properties which led to potent P2X(7)R antagonists with good disposition properties. Compound 33 (CE-224,535) was advanced to clinical studies for the treatment of rheumatoid arthritis.
Bioorganic & medicinal chemistry letters 06/2011; 21(12):3708-11. · 2.65 Impact Factor
-
Kevin K-C Liu,
Bruce A Lefker, Mark A Dombroski,
Phoebe Chiang,
Peter Cornelius,
Terrell A Patterson,
Yuan Zeng,
Stephanie Santucci,
Elizabeth Tomlinson,
Colleen P Gibbons,
Ravi Marala,
Janice A Brown,
Jimmy X Kong,
Eunsun Lee,
Wendy Werner,
Zane Wenzel,
Craig Giragossian,
Hou Chen,
Steven B Coffey
[show abstract]
[hide abstract]
ABSTRACT: Brain-penetrable proline amides were developed as 5HT2c agonists with more than 1000-fold binding selectivity against 5HT2b receptor. After medicinal chemistry optimization and SAR studies, orally active proline amides with robust efficacy in a rodent food intake inhibition model were uncovered.
Bioorganic & medicinal chemistry letters 01/2010; 20(7):2365-9. · 2.65 Impact Factor
-
Amit S Kalgutkar,
Heather L Hatch,
Frederick Kosea,
Hang T Nguyen,
Edna F Choo,
Kim F McClure,
Timothy J Taylor,
Kirk R Henne,
Alexander V Kuperman, Mark A Dombroski,
Michael A Letavic
[show abstract]
[hide abstract]
ABSTRACT: The disposition of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine (1), a potent and selective inhibitor of mitogen activated protein (MAP) kinase p38alpha, was characterized in several animal species in support of its selection for preclinical safety studies and potential clinical development. 1 demonstrated generally favorable pharmacokinetic properties in all species examined. Following intravenous (i.v.) administration, 1 exhibited low volumes of distribution at steady state (Vd(ss)) ranging from 0.4-1.3 l/kg (2.4-26 l/m(2)) in the rat, dog and monkey. Systemic plasma clearance was low in cynomolgus monkeys (6.00 ml/min/kg, 72.0 ml/min/m(2)) and Sprague-Dawley rats (7.65+/-1.08 ml/min/kg, 45.9+/-6.48 ml/min/m(2) in male rats and 3.15+/-0.27 ml/min/kg, 18.9+/-1.62 ml/min/m(2) in female rats) and moderate in beagle dogs (12.3+/-5.1 ml/min/kg, 246+/-102 ml/min/m(2)) resulting in plasma half-lives ranging from 1 to 5 h in preclinical species. Moderate to high bioavailability of 1 was observed in rats (30-65%), dogs (87%) and monkeys (40%) after oral (p.o.) dosing consistent with the in vitro absorption profile of 1 in the Caco-2 permeability assay. In rats, the oral pharmacokinetics were dose dependent over the dose range studied (5, 50 and 100 mg/kg). The principal route of clearance of 1 in rat, dog, monkey and human liver microsomes and in vivo in preclinical species involved oxidative metabolism mediated by cytochrome P450 enzymes. The major metabolic fate of 1 in preclinical species and humans involved hydroxylation on the isopropyl group to yield the tertiary alcohol metabolite 2. In human liver microsomes, this transformation was catalysed by CYP3A4 as judged from reaction phenotyping analysis using isozyme-specific inhibitors and recombinant CYP enzymes. Metabolite 2 was also shown to possess inhibitory potency against p38alpha in a variety of in vitro assays. 1 as well as the active metabolite 2 were moderately to highly bound to plasma proteins (f(u) approximately 0.1-0.33) in rat, mouse, dog, monkey and human. 1 as well as the active metabolite 2 did not exhibit competitive inhibition of the five major cytochrome P450 enzymes namely CYP1A2, 2C9, 2C19, 2D6 and 3A4 (IC(50)>50 microM). Overall, these results indicate that the absorption, distribution, metabolism and excretion (ADME) profile of 1 is relatively consistent across preclinical species and predict potentially favorable pharmacokinetic properties in humans, supporting its selection for toxicity/safety assessment studies and possible investigations in humans as an anti-inflammatory agent.
Biopharmaceutics & Drug Disposition 11/2006; 27(8):371-86. · 2.07 Impact Factor
-
Kim F McClure,
Michael A Letavic,
Amit S Kalgutkar,
Christopher A Gabel,
Laurent Audoly,
John T Barberia,
John F Braganza,
Demetrius Carter,
Thomas J Carty,
Santo R Cortina, [......],
Kevin M Peese,
Francis J Sweeney,
Timothy J Taylor,
Catherine E Trebino,
Yuriy A Abramov,
Ellen R Laird,
Walter A Volberg,
Jun Zhou,
Justin Bach,
Franco Lombardo
[show abstract]
[hide abstract]
ABSTRACT: The synthesis, structure-activity relationship, in vivo activity, and metabolic profile for a series of triazolopyridine-oxazole based p38 inhibitors are described. The deficiencies of the lead structure in the series, CP-808844, were overcome by changes to the C4 aryl group and the triazole side-chain culminating in the identification of several potential clinical candidates.
Bioorganic & Medicinal Chemistry Letters 09/2006; 16(16):4339-44. · 2.55 Impact Factor
-
Kim F McClure,
Yuriy A Abramov,
Ellen R Laird,
John T Barberia,
Weiling Cai,
Thomas J Carty,
Santo R Cortina,
Dennis E Danley,
Alan J Dipesa,
Kathleen M Donahue, [......],
Thomas R Hynes,
Peter K Lemotte,
Mahmoud N Mansour,
Eric S Marr,
Michael A Letavic,
Jayvardhan Pandit,
David B Ripin,
Francis J Sweeney,
Douglas Tan,
Yong Tao
[show abstract]
[hide abstract]
ABSTRACT: Mimics of the benzimidazolone nucleus found in inhibitors of p38 kinase are proposed, and their theoretical potential as bioisosteres is described. A set of calculated descriptors relevant to the anticipated binding interaction for the fragments 1-methyl-1H-benzotriazole 5, 3-methyl-benzo[d]isoxazole 3, and 3-methyl-[1,2,4]triazolo[4,3-a]pyridine 4, pyridine 1, and 1,3-dimethyl-1,3-dihydro-benzoimidazol-2-one 2 are reported. The design considerations and synthesis of p38 inhibitors based on these H-bond acceptor fragments is detailed. Comparative evaluation of the pyridine-, benzimidazolone-, benzotriazole-, and triazolopyridine-based inhibitors shows the triazoles 20 and 25 to be significantly more potent experimentally than the benzimidazolone after which they were modeled. An X-ray crystal structure of 25 bound to the active site shows that the triazole group serves as the H-bond acceptor but unexpectedly as a dual acceptor, inducing movement of the crossover connection of p38alpha. The computed descriptors for the hydrophobic and pi-pi interaction capacities were the most useful in ranking potency.
Journal of Medicinal Chemistry 10/2005; 48(18):5728-37. · 5.25 Impact Factor
-
Mark A Dombroski,
Michael A Letavic,
Kim F McClure,
John T Barberia,
Thomas J Carty,
Santo R Cortina,
Csilla Csiki,
Alan J Dipesa,
Nancy C Elliott,
Christopher A Gabel,
Crystal K Jordan,
Jeff M Labasi,
William H Martin,
Kevin M Peese,
Ingrid A Stock,
Linne Svensson,
Francis J Sweeney,
Chul H Yu
[show abstract]
[hide abstract]
ABSTRACT: The synthesis and in vitro p38 alpha activity of a novel series of benzimidazolone inhibitors is described. The p38 alpha SAR is consistent with a mode of binding wherein the benzimidazolone carbonyl serves as the H-bond acceptor to Met109 of p38 alpha in a manner analogous to the pyridine nitrogen of prototypical pyridylimidazole p38 inhibitors. Potent p38 alpha activity comparable to that of several previously reported p38 inhibitors is observed for this novel chemotype.
Bioorganic & Medicinal Chemistry Letters 03/2004; 14(4):919-23. · 2.55 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Stimulus-induced posttranslational processing of human monocyte interleukin-1beta (IL-1beta) is accompanied by major changes to the intracellular ionic environment, activation of caspase-1, and cell death. Certain diarylsulfonylureas inhibit this response, and are designated cytokine release inhibitory drugs (CRIDs). CRIDs arrest activated monocytes so that caspase-1 remains inactive and plasma membrane latency is preserved. Affinity labeling with [(14)C]CRIDs and affinity chromatography on immobilized CRID were used in seeking potential protein targets of their action. Following treatment of intact human monocytes with an epoxide-bearing [(14)C]CRID, glutathione S-transferase (GST) Omega 1-1 was identified as a preferred target. Moreover, labeling of this polypeptide correlated with irreversible inhibition of ATP-induced IL-1beta posttranslational processing. When extracts of human monocytic cells were chromatographed on a CRID affinity column, GST Omega 1-1 bound selectively to the affinity matrix and was eluted by soluble CRID. Recombinant GST Omega 1-1 readily incorporated [(14)C]CRID epoxides, but labeling was negated by co-incubation with S-substituted glutathiones or by mutagenesis of the catalytic center Cys(32) to alanine. Peptide mapping by high performance liquid chromatography-mass spectrometry also demonstrated that Cys(32) was the site of modification. Although S-alkylglutathiones did not arrest ATP-induced IL-1beta posttranslational processing or inhibit [(14)C]CRID incorporation into cell-associated GST Omega 1-1, a glutathione-CRID adduct effectively demonstrated these attributes. Therefore, the ability of CRIDs to arrest stimulus-induced IL-1beta posttranslational processing may be attributable to their interaction with GST Omega 1-1.
Journal of Biological Chemistry 06/2003; 278(19):16567-78. · 4.77 Impact Factor
